Depakote Capsule
Product Images NDC 0074-6114

9 FDA label images from Abbvie Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Depakote (NDC 0074-6114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Divalproex Sodium Is A Stable Co-ordination Compound Comprised Of Sodium Valproate And Valproic Acid In A 1:1 Molar Relationship And Formed During The Partial Neutralization Of Valproic Acid With 0.5 Equivalent Of Sodium Hydroxide. Chemically It Is Designated As Sodium Hydrogen Bis(2-propylpentanoate). Divalproex Sodium Has The Following Structure: (Depakote Sprinkle Capsules Spl 01)

Divalproex Sodium Is A Stable Co-ordination Compound Comprised Of Sodium Valproate And Valproic Acid In A 1:1 Molar Relationship And Formed During The Partial Neutralization Of Valproic Acid With 0.5 Equivalent Of Sodium Hydroxide. Chemically It Is Designated As Sodium Hydrogen Bis(2-propylpentanoate). Divalproex Sodium Has The Following Structure: (Depakote Sprinkle Capsules Spl 01)
Chemical structure of divalproex sodium, the active ingredient in Depakote Sprinkles 125 mg capsules by AbbVie Inc. The structure shows the valproate moiety complexed with sodium and the carboxylate functional groups.*
FDA Label Image

Figure 1 (Depakote Sprinkle Capsules Spl 02)

Figure 1 (Depakote Sprinkle Capsules Spl 02)
A cumulative distribution plot comparing the percentage reduction in CPS (clinical parameter) rate between patients taking Depakote Sprinkles and a placebo. The y-axis shows percent reduction in CPS rate from -100% to 100%, and the x-axis shows the percentage of patients from 0 to 100. The graph has lines for Depakote and placebo, indicating improvement or worsening in patient response.*
FDA Label Image

Figure 2 (Depakote Sprinkle Capsules Spl 03)

Figure 2 (Depakote Sprinkle Capsules Spl 03)
A line graph depicting the percentage reduction in CPS rate on the y-axis versus percentage of patients on the x-axis, comparing high dose and low dose groups. The graph shows lines indicating improvement and worsening, with high dose represented by a solid line and low dose by a dashed line.*
FDA Label Image

1 (Depakote Sprinkle Capsules Spl 04)

1 (Depakote Sprinkle Capsules Spl 04)
Depakote Sprinkles 125 mg oral capsule showing imprint on a white capsule. The imprint reads 'TRIC 4' on one side and 'DEPAKOTE SPRINKLES 125 MG' on the other, indicating the product name and dosage strength. The capsule is displayed against a neutral background. Labeler is AbbVie Inc.*
FDA Label Image

2 (Depakote Sprinkle Capsules Spl 05)

2 (Depakote Sprinkle Capsules Spl 05)
An instructional illustration showing a close-up of a hand holding a Depakote Sprinkles 125 mg capsule, indicating the direction to open the capsule by twisting or pulling apart. The image is intended to demonstrate how to open the capsule for administration.*
FDA Label Image

3 (Depakote Sprinkle Capsules Spl 06)

3 (Depakote Sprinkle Capsules Spl 06)
An illustration showing a hand holding an open Depakote Sprinkles capsule, with small granules pouring out onto a surface. The image demonstrates the capsule contents, which are small sprinkle-like particles.*
FDA Label Image

4 (Depakote Sprinkle Capsules Spl 07)

4 (Depakote Sprinkle Capsules Spl 07)
An illustration showing a child with an open mouth being fed medication from a spoon held by an adult hand. The image depicts the oral administration of medication, likely representing how to give Depakote Sprinkles capsules' contents to a child.*
FDA Label Image

Ndc 0074–6114–13 100 Sprinkle Capsules Depakote® Sprinkle Capsules Divalproex Sodium Delayed Release Capsules 125 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Sprinkle Capsules Spl 08)

Ndc 0074–6114–13 100 Sprinkle Capsules Depakote® Sprinkle Capsules Divalproex Sodium Delayed Release Capsules 125 mg Valproic Acid Activity Dispense The Accompanying Medication Guide To Each Patient. Rx Only Abbvie (Depakote Sprinkle Capsules Spl 08)
Depakote Sprinkles 125 mg Sprinkle Capsules label by AbbVie Inc. The label indicates the active ingredient as divalproex sodium delayed release capsules, with a package count of 100 capsules. It includes storage instructions, a barcode, a 2D barcode placeholder, and a caution about the capsule appearance and dispensing conditions.*
FDA Label Image

Description: Delisted Image (Depakote Sprinkle Capsules Spl 09)

Description: Delisted Image (Depakote Sprinkle Capsules Spl 09)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.